EA201892412A1 - Антитела, распознающие тау - Google Patents
Антитела, распознающие тауInfo
- Publication number
- EA201892412A1 EA201892412A1 EA201892412A EA201892412A EA201892412A1 EA 201892412 A1 EA201892412 A1 EA 201892412A1 EA 201892412 A EA201892412 A EA 201892412A EA 201892412 A EA201892412 A EA 201892412A EA 201892412 A1 EA201892412 A1 EA 201892412A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies recognizing
- tau
- recognizing tau
- antibodies
- symptoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Peptides Or Proteins (AREA)
Abstract
В настоящем изобретении предложены антитела, которые специфично связываются с тау. Антитела ингибируют или отсрочивают связанные с тау патологии и связанные ухудшения симптомов.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662330800P | 2016-05-02 | 2016-05-02 | |
PCT/IB2017/052545 WO2017191561A1 (en) | 2016-05-02 | 2017-05-02 | Antibodies recognizing tau |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201892412A1 true EA201892412A1 (ru) | 2019-05-31 |
Family
ID=58709516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201892412A EA201892412A1 (ru) | 2016-05-02 | 2017-05-02 | Антитела, распознающие тау |
Country Status (17)
Country | Link |
---|---|
US (2) | US10906964B2 (ru) |
EP (1) | EP3452509A1 (ru) |
JP (1) | JP7194985B2 (ru) |
KR (2) | KR102533675B1 (ru) |
CN (1) | CN109415434B (ru) |
AU (1) | AU2017259039B2 (ru) |
BR (1) | BR112018072394A2 (ru) |
CA (1) | CA3022765A1 (ru) |
CO (1) | CO2018012987A2 (ru) |
CU (1) | CU24538B1 (ru) |
EA (1) | EA201892412A1 (ru) |
MX (1) | MX2018013386A (ru) |
MY (1) | MY197413A (ru) |
PE (1) | PE20190208A1 (ru) |
SG (1) | SG11201809331RA (ru) |
WO (1) | WO2017191561A1 (ru) |
ZA (1) | ZA201808043B (ru) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6674888B2 (ja) | 2013-03-13 | 2020-04-01 | プロセナ バイオサイエンシーズ リミテッド | タウ免疫療法 |
EA201892417A1 (ru) | 2016-05-02 | 2019-05-31 | Протена Биосайенсис Лимитед | Антитела, распознающие тау |
FI3452507T3 (fi) | 2016-05-02 | 2022-12-15 | Tau-immuunihoito | |
KR102533675B1 (ko) | 2016-05-02 | 2023-05-22 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
WO2018152359A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
CN110881274A (zh) | 2017-05-02 | 2020-03-13 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
JP6851549B2 (ja) | 2017-10-16 | 2021-03-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗タウ抗体及びその使用 |
AU2019232630A1 (en) * | 2018-03-05 | 2020-09-24 | Janssen Pharmaceutica Nv | Assays to detect neurodegeneration |
BR112021016947A2 (pt) | 2019-03-03 | 2021-11-03 | Prothena Biosciences Ltd | Anticorpos que reconhecem tau |
WO2020227515A1 (en) | 2019-05-07 | 2020-11-12 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
JP2023526500A (ja) | 2020-05-19 | 2023-06-21 | オター プロシーナ リミテッド | アルツハイマー病の処置のためのマルチエピトープワクチン |
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5674703A (en) | 1992-12-02 | 1997-10-07 | Woo; Savio L. C. | Episomal vector systems and related methods |
US5837242A (en) | 1992-12-04 | 1998-11-17 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
ES2318848T3 (es) | 1993-09-14 | 2009-05-01 | Pharmexa Inc. | Peptidos que se unen a pan dr para potenciar la respuesta inmunitaria. |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5877218A (en) | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
US7427392B1 (en) * | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
DK1005368T3 (da) | 1997-03-10 | 2010-01-04 | Ottawa Hospital Res Inst | Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
DE60045319D1 (de) | 1999-02-05 | 2011-01-13 | Samsung Electronics Co Ltd | Verfahren und Vorrichtung zum Wiederauffinden von Texturbildern |
TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
EP1539233B1 (en) | 2001-07-12 | 2011-04-27 | FOOTE, Jefferson | Super humanized antibodies |
US6924360B2 (en) | 2001-12-28 | 2005-08-02 | Abgenix, Inc. | Antibodies against the MUC18 antigen |
DE50308030D1 (de) | 2002-11-29 | 2007-10-04 | Boehringer Ingelheim Pharma | Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen |
DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
AU2005291486A1 (en) | 2004-10-01 | 2006-04-13 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Novel antibodies directed to the mammalian EAG1 ion channel protein |
JP4620739B2 (ja) | 2004-11-10 | 2011-01-26 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Cho細胞に対する細胞保存戦略を最適化するためのフローサイトメトリ分析の使用 |
CA2591665C (en) | 2004-12-20 | 2015-05-05 | Crucell Holland B.V. | Binding molecules capable of neutralizing west nile virus and uses thereof |
WO2006074071A1 (en) | 2004-12-30 | 2006-07-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Framework residue substituted humanized col-1 antibodies and their use |
US8236933B2 (en) * | 2005-04-13 | 2012-08-07 | Garvan Institute Of Medical Research | Modified animal lacking functional PYY gene, monoclonal antibodies that bind PYY isoforms and uses therefor |
US8012936B2 (en) * | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
US8301398B2 (en) | 2006-06-22 | 2012-10-30 | Walter And Eliza Hall Institute Of Medical Research | Structure of the insulin receptor ectodomain |
US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
ES2523915T5 (es) | 2006-12-01 | 2022-05-26 | Seagen Inc | Agentes de unión a la diana variantes y usos de los mismos |
CN101626782B (zh) | 2006-12-01 | 2013-03-27 | 梅达雷克斯公司 | 结合cd22的人抗体及其用途 |
SI2436696T1 (sl) | 2007-01-05 | 2017-10-30 | University Of Zurich | Anti-beta-amiloidno protitelo in načini njegove uporabe |
EP2118300B1 (en) | 2007-02-23 | 2015-05-27 | Prothena Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
EP2522730A1 (en) | 2007-03-02 | 2012-11-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Improvement of protein production |
EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
JP2009056790A (ja) | 2007-09-03 | 2009-03-19 | Takao Otogawa | ファイル用ポケット |
EP2497783A3 (en) | 2007-09-26 | 2013-04-17 | U3 Pharma GmbH | Heparin-binding epidermal growth factor-like growth factor antigen binding proteins |
EP2220122A2 (en) | 2007-11-13 | 2010-08-25 | Teva Biopharmaceuticals USA, Inc. | Humanized antibodies against tl1a |
JP2010014691A (ja) | 2008-06-20 | 2010-01-21 | Igaku Seibutsugaku Kenkyusho:Kk | 腹水中のメソテリン及び/又は巨核球増強因子を検出するための方法、キット、試薬及び装置 |
PE20110774A1 (es) | 2008-08-18 | 2011-10-13 | Amgen Fremont Inc | Anticuerpos para ccr2 |
US9605054B2 (en) | 2009-02-23 | 2017-03-28 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating a tauopathy |
CA2939492C (en) | 2009-05-13 | 2019-03-19 | Genzyme Corporation | Anti-human cd52 immunoglobulins |
CN106390107B (zh) | 2009-06-10 | 2019-12-31 | 纽约大学 | 病理tau蛋白的免疫靶向 |
US20110009628A1 (en) | 2009-07-08 | 2011-01-13 | Haiyan Liu | Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same |
US20110045534A1 (en) | 2009-08-20 | 2011-02-24 | Cell Signaling Technology, Inc. | Nucleic Acid Cassette For Producing Recombinant Antibodies |
EP2512600A2 (en) | 2009-12-18 | 2012-10-24 | Amgen Inc. | Wise binding agents and epitopes |
JP5697044B2 (ja) | 2010-01-08 | 2015-04-08 | 国立大学法人京都大学 | タウオパチー治療用ワクチン |
AU2011221226A1 (en) | 2010-02-23 | 2012-08-16 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
JP2013523182A (ja) | 2010-04-15 | 2013-06-17 | アボット・ラボラトリーズ | アミロイドベータ結合タンパク質 |
ITRM20100320A1 (it) | 2010-06-11 | 2011-12-11 | Consiglio Nazionale Ricerche | Metodo per la diagnostica e il trattamento delle taupatie |
US20120023911A1 (en) | 2010-07-28 | 2012-02-02 | Gm Global Technology Operations, Inc. | Detection of exhaust particulate filter substrate failure |
EA031698B1 (ru) | 2010-10-11 | 2019-02-28 | Байоджен Интернэшнл Нейросайенз Гмбх | Человеческие анти-тау антитела |
US20140050733A1 (en) | 2011-02-07 | 2014-02-20 | Dale B. Schenk | Apoe immunotherapy |
WO2012149365A2 (en) | 2011-04-27 | 2012-11-01 | Northwestern University | Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies |
GB201109238D0 (en) | 2011-06-01 | 2011-07-13 | Antitope Ltd | Antibodies |
GB201111361D0 (en) * | 2011-07-04 | 2011-08-17 | Nordic Bioscience As | Biochemical markers for neurodegenerative conditions |
GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
BR112014004162A2 (pt) | 2011-08-22 | 2018-04-24 | Cangene Corp | anticorpos contra clostridium difficile |
MY183989A (en) | 2011-09-19 | 2021-03-17 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
AR092779A1 (es) | 2011-10-07 | 2015-05-06 | Ac Immune Sa | Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau |
MY184037A (en) | 2012-03-28 | 2021-03-17 | Sanofi Sa | Antibodies to bradykinin b1 receptor ligands |
CA2869438C (en) | 2012-04-05 | 2021-08-17 | Ac Immune S.A. | Humanized tau antibody |
BR112014025974A2 (pt) | 2012-04-18 | 2017-06-27 | Du Pont | folha em camadas. |
RU2668159C2 (ru) | 2012-07-03 | 2018-09-26 | Вашингтон Юниверсити | Антитела против тау |
BR112015003326A2 (pt) | 2012-08-16 | 2017-07-04 | Ipierian Inc | métodos de tratamento de uma tauopatia |
US20140056901A1 (en) | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
CA2887933A1 (en) | 2012-10-12 | 2014-04-17 | Arizona Board Of Agents, On Behalf Of Arizona State University | Antibody based reagents that specifically recognize toxic oligomeric forms of tau |
US9200068B2 (en) | 2012-12-18 | 2015-12-01 | Regents Of The University Of Minnesota | Compositions and methods related to tauopathy |
US9598484B2 (en) * | 2012-12-21 | 2017-03-21 | Biogen Ma Inc. | Human anti-tau antibodies |
JP6674888B2 (ja) * | 2013-03-13 | 2020-04-01 | プロセナ バイオサイエンシーズ リミテッド | タウ免疫療法 |
US9688747B2 (en) * | 2013-03-15 | 2017-06-27 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
WO2014152773A1 (en) | 2013-03-15 | 2014-09-25 | The Trustees Of The University Of Pennsylvania | Blood biomarkers that predict persistent cognitive dysfunction after concussion |
CN105658672A (zh) | 2013-08-22 | 2016-06-08 | 阿塞勒隆制药公司 | TGF-β受体II型变体及其用途 |
CN110156893B (zh) | 2013-12-17 | 2023-03-03 | 基因泰克公司 | 抗cd3抗体及使用方法 |
US9629801B2 (en) | 2014-01-10 | 2017-04-25 | Wisconsin Alumni Research Foundation | Blood-brain barrier targeting antibodies |
US20150253341A1 (en) | 2014-02-10 | 2015-09-10 | Merck Sharp & Dohme Corp. | Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry |
TWI664190B (zh) | 2014-06-27 | 2019-07-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
WO2016079597A1 (en) * | 2014-11-19 | 2016-05-26 | Axon Neuroscience Se | Humanized tau antibodies in alzheimer's disease |
CA2874083C (en) | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
CN117069841A (zh) | 2015-10-06 | 2023-11-17 | 艾利妥 | 抗trem2抗体及其使用方法 |
FI3452507T3 (fi) | 2016-05-02 | 2022-12-15 | Tau-immuunihoito | |
KR102533675B1 (ko) | 2016-05-02 | 2023-05-22 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
EA201892417A1 (ru) | 2016-05-02 | 2019-05-31 | Протена Биосайенсис Лимитед | Антитела, распознающие тау |
WO2018156250A1 (en) | 2017-02-21 | 2018-08-30 | Remd Biotherapeutics, Inc. | Cancer treatment using antibodies that bind cytotoxic t-lymphocyte antigen-4 (ctla-4) |
CN110881274A (zh) | 2017-05-02 | 2020-03-13 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
PE20211777A1 (es) | 2018-11-08 | 2021-09-08 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
CA3118818A1 (en) | 2018-11-08 | 2020-05-14 | Prothena Biosciences Limited | Antibodies recognizing tau |
PE20211709A1 (es) | 2019-02-08 | 2021-09-01 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
BR112021016947A2 (pt) | 2019-03-03 | 2021-11-03 | Prothena Biosciences Ltd | Anticorpos que reconhecem tau |
-
2017
- 2017-05-02 KR KR1020187033955A patent/KR102533675B1/ko active IP Right Grant
- 2017-05-02 WO PCT/IB2017/052545 patent/WO2017191561A1/en unknown
- 2017-05-02 CU CU2018000135A patent/CU24538B1/es unknown
- 2017-05-02 US US16/097,445 patent/US10906964B2/en active Active
- 2017-05-02 BR BR112018072394-0A patent/BR112018072394A2/pt unknown
- 2017-05-02 CN CN201780041075.6A patent/CN109415434B/zh active Active
- 2017-05-02 EA EA201892412A patent/EA201892412A1/ru unknown
- 2017-05-02 MX MX2018013386A patent/MX2018013386A/es unknown
- 2017-05-02 KR KR1020237016259A patent/KR20230070336A/ko not_active Application Discontinuation
- 2017-05-02 SG SG11201809331RA patent/SG11201809331RA/en unknown
- 2017-05-02 EP EP17723769.0A patent/EP3452509A1/en active Pending
- 2017-05-02 AU AU2017259039A patent/AU2017259039B2/en active Active
- 2017-05-02 JP JP2018557809A patent/JP7194985B2/ja active Active
- 2017-05-02 CA CA3022765A patent/CA3022765A1/en active Pending
- 2017-05-02 PE PE2018002310A patent/PE20190208A1/es unknown
- 2017-05-02 MY MYPI2018704074A patent/MY197413A/en unknown
-
2018
- 2018-11-28 ZA ZA2018/08043A patent/ZA201808043B/en unknown
- 2018-11-29 CO CONC2018/0012987A patent/CO2018012987A2/es unknown
-
2020
- 2020-11-04 US US17/089,599 patent/US20220372118A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20220372118A1 (en) | 2022-11-24 |
AU2017259039A1 (en) | 2018-10-11 |
MX2018013386A (es) | 2019-02-28 |
JP2019525728A (ja) | 2019-09-12 |
PE20190208A1 (es) | 2019-02-07 |
ZA201808043B (en) | 2020-02-26 |
US20190330316A1 (en) | 2019-10-31 |
CN109415434B (zh) | 2022-12-30 |
MY197413A (en) | 2023-06-16 |
EP3452509A1 (en) | 2019-03-13 |
AU2017259039B2 (en) | 2024-05-09 |
BR112018072394A2 (pt) | 2019-02-19 |
CU20180135A7 (es) | 2019-06-04 |
KR20230070336A (ko) | 2023-05-22 |
CO2018012987A2 (es) | 2018-12-14 |
CU24538B1 (es) | 2021-08-06 |
SG11201809331RA (en) | 2018-11-29 |
CN109415434A (zh) | 2019-03-01 |
KR102533675B1 (ko) | 2023-05-22 |
US10906964B2 (en) | 2021-02-02 |
KR20190015703A (ko) | 2019-02-14 |
CA3022765A1 (en) | 2017-11-09 |
WO2017191561A1 (en) | 2017-11-09 |
JP7194985B2 (ja) | 2022-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201892417A1 (ru) | Антитела, распознающие тау | |
EA201892412A1 (ru) | Антитела, распознающие тау | |
EA202092435A2 (ru) | Моноклональные антитела против bcma | |
EA201692539A1 (ru) | Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками | |
EA201791164A1 (ru) | Гетеродимерные антитела, связывающие cd3 и cd38 | |
EA201890712A1 (ru) | Антитела к про-/латентному миостатину и их применения | |
BR112015022260A8 (pt) | imunoterapia com tau | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
EA201792467A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
EA201792589A1 (ru) | Антитела против cd123 и конъюгаты указанных антител | |
EA201790984A1 (ru) | Анти-cd79b антитела и способы их применения | |
EA201791139A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
EA201890131A1 (ru) | Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38 | |
EA202091315A2 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
EA201691610A1 (ru) | Анти-jagged1 антитела и способы применения | |
MX2019013045A (es) | Anticuerpos que reconocen tau. | |
EA201991720A1 (ru) | Антитела к альфа-синуклеину и их применения | |
EA201792220A1 (ru) | Опосредуемая антителом нейтрализация вируса чикунгунья | |
EA201992756A2 (ru) | Антитела против cd48 и их конъюгаты | |
EA202091350A1 (ru) | Связывающие молекулы, специфично связывающиеся с тау-белком | |
EA201892716A1 (ru) | Антитела к фактору свертывания xi | |
EA201992281A1 (ru) | Связывающие молекулы, специфично связывающиеся с тау-белком | |
EA201891299A1 (ru) | Терапевтические антитела к cd9 | |
EA201890739A1 (ru) | Анти-s100a8 для лечения лейкемии | |
EA201991876A1 (ru) | Антитела против фактора d и их применения |